300294 China Resources Boya Bio-pharmaceutical Group
- 32.72
- -0.59-1.77%
China Resources Boya Bio-pharmaceutical Group News
Morgan Stanley Starts China Resources Boya Bio-pharmaceutical Group at Equal-weight; Price Target Is 37 Yuan
12:13 AM EDT, 05/27/2024 (MT Newswires) -- Morgan Stanley Starts China Resources Boya Bio-pharmaceutical Group at Equal-weight; Price Target is 37 Yuan Price (RMB): ¥32.46, Change: ¥-0.15, Percent Cha
Liberal Arts Biotech (300294.SZ): On May 20, 2024, the number of shareholders was 18,115
Gelonghui, May 21丨Liberal Arts Biotech (300294.SZ) said on the investor interactive platform that the number of shareholders in the company's consolidated register including credit accounts was 18,115 on May 20, 2024.
Optimism for China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Has Grown This Past Week, Despite Five-year Decline in Earnings
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. For example, long term China Resources Boya Bio-ph
China Resources Pharmaceutical (03320): China Resources Liberal Arts Biotech's net profit for the first quarter of 152.2 million yuan decreased by 12.97% year-on-year
China Resources Pharmaceuticals (03320) announced that China Resources Biotech, a subsidiary of the company, will be 3 as of March 31, 2024...
Liberal Arts Biotech (300294.SZ) announced first-quarter results, net profit of 152 million yuan, a decrease of 10.74%
Liberal Arts Biotech (300294.SZ) released its report for the first quarter of 2024, achieving 4.4 operating income during the reporting period...
Retail Investors Are China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥837m Last Week
Key Insights Significant control over China Resources Boya Bio-pharmaceutical GroupLtd by retail investors implies that the general public has more power to influence management and governance-related
Liberal Arts Biotech (300294.SZ) plans to pay 3 yuan for 10 shares to be deducted from interest on April 26
Liberal Arts Biotech (300294.SZ) announced that the company's 2023 equity distribution plan: every 10...
Liberal Arts Biotech (300294.SZ): In 2023, the company's VIII factor and PCC sales trends were good, and overall sales grew rapidly
Gelonghui, April 2, 丨 Boya Biotech (300294.SZ) was surveyed by a specific target on April 1, 2024. Regarding “the sales situation of the company's factor VIII, PCC and other products,” the company replied that in 2023, the company's sales trend of Factor VIII and PCC was good, and overall sales were growing rapidly. According to hospital CPA sample statistics, the company's prothrombin complex (PCC) ranks third in the industry. The company attaches importance to building an academic system and continuously improving product coverage and penetration rate.
Liberal Arts Biotech (300294.SZ): In 2023, the company collected 467.3 tons of pulp, an increase of 6.47% over the previous year
Gelonghui, April 2, 丨 Boya Biotech (300294.SZ) was surveyed by specific subjects on April 1, 2024. Regarding “the company's pulp collection situation and future trends,” the company replied that in 2023, the company's pulp collection volume was 467.3 tons, an increase of 6.47% over the previous year. There was a negative year-on-year increase in pulping volume from January to July 2023, but positive year-on-year growth was achieved since August, showing a trend of low and high levels. Overall, the performance of pulp collection is steady and improving. The company focuses on the business policy of “setting goals, setting standards, heavy rewards and penalties, and strong execution”, innovates the new development model and thoroughly implements “new development”
China Resources Boya Bio-pharmaceutical GroupLtd's (SZSE:300294) Soft Earnings Don't Show The Whole Picture
Soft earnings didn't appear to concern China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) shareholders over the last week. We did some digging, and we believe the earnings are stro
Liberal Arts Biotech (300294.SZ): The price of the company's products is stable
On March 27, Gelonghui Biotech (300294.SZ) said on the investor interactive platform that the price of the company's products is stable. The cost of intravenous human immunoglobulin increased by 16.68% in 2023, mainly due to the increase in the revenue scale of this product.
China Resources Pharmaceuticals (03320.HK): Liberal Arts Biotech achieved net profit of 237 million yuan in 2023 and plans to pay 10 to 3 yuan
On March 25, Ge Longhui Pharmaceutical (03320.HK) announced that in 2023, Liberal Arts Biotech (300294.SZ) achieved operating income of RMB 2,652 billion, down 3.87% year on year; net profit attributable to shareholders of Liberal Arts Biotech was 237 million yuan, down 45.06% year on year; net profit attributable to shareholders of Liberal Arts Biotech after deducting non-recurring profit and loss was 143 million yuan, down 63.51% year on year; basic income per share is 0.47 yuan; it plans to distribute a cash dividend of 3 yuan (tax included) for every 10 shares to all shareholders.
These 4 Measures Indicate That China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294) Is Using Debt Safely
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how
Liberal Arts Biotech (300294.SZ): Net profit for 2023 decreased by 45.06% to 237 million yuan, plans to pay 10 to 3 yuan
Gelonghui, March 22丨Liberal Arts Biotech (300294.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 2,652 billion yuan, a year-on-year decrease of 3.87%; net profit attributable to shareholders of listed companies was 237 million yuan, down 45.06% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 143 million yuan, down 63.51% year on year; basic income per share was 0.47 yuan; it plans to distribute a cash dividend of 3 yuan (tax included) for every 10 shares to all shareholders.
Liberal Arts Biotech (300294.SZ) Performance Report: Net profit for 2023 was 237 million yuan, a year-on-year decrease of 45.06%
Gelonghui, March 13 | Liberal Arts Biotech (300294.SZ) announced its 2023 annual performance report. In 2023, the company achieved total operating income of 2,652 billion yuan, a year-on-year decrease of 3.87%; total profit of 354 million yuan, a year-on-year decrease of 33.51%; net profit attributable to shareholders of listed companies was 237 million yuan, a decrease of 45.06% over the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss, of 143 million yuan; basic earnings per share were 0.47 yuan.
Liberal Arts Biotech (300294.SZ): No business-level cooperation with Tiantan Biotech
Gelonghui March 13 | Liberal Arts Biotech (300294.SZ) said on the investor interactive platform that the company has no business-level cooperation with Tiantan Biotech. The company has always followed industry benchmarks as an example.
Liberal Arts Biotech (300294.SZ): The number of shareholders on the consolidated register including credit accounts was 22,353 on March 8, 2024
Gelonghui March 13 | Liberal Arts Biotech (300294.SZ) said on the investor interactive platform that the number of shareholders in the company's consolidated register including credit accounts on March 8, 2024 was 22,353.
Is China Resources Boya Bio-pharmaceutical Group Co.,Ltd's (SZSE:300294) Recent Price Movement Underpinned By Its Weak Fundamentals?
With its stock down 21% over the past three months, it is easy to disregard China Resources Boya Bio-pharmaceutical GroupLtd (SZSE:300294). It seems that the market might have completely ignored the
Guosheng Securities: Supply and demand resonate and state-owned capital enters a new development cycle in the blood products industry
The supply and demand for blood products continues to expand, and the nearly 60 billion market still has room for growth.
CR Boya Bio-Pharmaceutical Signs 29.5 Million Yuan Construction Contract for Blood Products Facility
China Resources Boya Bio-Pharmaceutical Group (SHE:300294) contracted Shenzhen Runzhi City Construction Management for the construction of the first phase of facilities for its blood products business
Analysis
Price Target
No Data
